TTC-352

About TTC Oncology

TTC Oncology is a clinical-stage biotechnology company focused on developing TTC-352, a novel ShERPA (Selective Human Estrogen Receptor Partial Agonist) for the treatment of metastatic ER+ breast cancer. The company was founded by a team of academic experts and is built on a worldwide license from the University of Illinois Chicago (UIC). Its core strategy is to address the significant unmet need in endocrine-resistant breast cancer by offering a safer alternative to high-dose estrogen therapy, with the drug having already completed a Phase 1 clinical trial.

Therapeutic Areas